AMELUZ

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Ireland, Lithuania, Poland, Spain, UK.

Active ingredients

The drug AMELUZ contains one active pharmaceutical ingredient (API):

1	Aminolevulinic acid UNII V35KBM8JGR - AMINOLEVULINIC ACID HYDROCHLORIDE
	5-Aminolevulinic acid (5-ALA) is a natural biochemical precursor of heme that is metabolised in a series of enzymatic reactions to fluorescent porphyrins, particularly PPIX. 5-ALA synthesis is regulated by an intracellular pool of free heme via a negative feedback mechanism. Administration of excess exogenous 5-ALA avoids the negative feedback control, and accumulation of PPIX occurs in target tissue. In the presence of visible light, fluorescence of PPIX (photodynamic effect) in certain target tissues can be used for photodynamic diagnosis.
	Read more about Aminolevulinic acid

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AMELUZ Gel	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XD04	Aminolevulinic acid	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XD Sensitizers used in photodynamic/radiation therapy
Discover more medicines within L01XD04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1552799
ES	Centro de información online de medicamentos de la AEMPS	11740001
GB	Medicines & Healthcare Products Regulatory Agency	262469
LT	Valstybinė vaistų kontrolės tarnyba	1064400
PL	Rejestru Produktów Leczniczych	100308580
US	FDA, National Drug Code	70621-101